Cost-Effective Alternative: Start Ezetimibe Immediately
For a statin-intolerant patient who cannot afford bempedoic acid, ezetimibe is the most cost-effective first-line alternative, providing 18% LDL-C reduction as monotherapy at a fraction of the cost. 1
Recommended Treatment Algorithm
First-Line: Ezetimibe
- Dose: 10 mg orally daily, with or without food 1
- LDL-C reduction: 18% as monotherapy 1
- Cost: Generically available and significantly cheaper than bempedoic acid 2
- Safety: Excellent tolerability profile, no muscle-related adverse effects 3
- Evidence: Has demonstrated cardiovascular event reduction in clinical trials 1
Second-Line Options if Ezetimibe Insufficient
Bile Acid Sequestrants (BAS)
- Colesevelam: 6 tablets daily or 3 tablets twice daily with meals 1
- LDL-C reduction: 15% as monotherapy; additional 10-16% when combined with low-to-moderate intensity statins 1
- Cost: More expensive than ezetimibe but cheaper than bempedoic acid 2
- Advantage: Can be used in true statin intolerance without muscle symptoms
- Disadvantage: GI side effects (constipation, bloating), pill burden, may interfere with absorption of other medications
Addressing Bempedoic Acid Cost Barriers
If the patient's cardiovascular risk is very high and ezetimibe alone is insufficient, explore these cost-reduction strategies for bempedoic acid 1:
- Patient assistance programs: Manufacturer offers programs for eligible patients 1
- Discount copay cards: Available for qualifying patients 1
- Prior authorization: Work with insurance to demonstrate statin intolerance and inadequate response to ezetimibe
Important caveat: Many patients do not pay the full retail price of $400 1
Clinical Considerations for Statin Intolerance
Confirm True Statin Intolerance
Before abandoning statins entirely, the 2022 ACC guidelines recommend attempting 1:
- At least 2-3 different statins
- Lowest FDA-approved dose
- Alternative dosing regimens (e.g., every-other-day dosing)
Consider Referral
Refer to a lipid specialist if 1:
- Patient has ASCVD and baseline LDL-C ≥190 mg/dL
- Intolerance to at least 2-3 statin therapies documented
- Unable to achieve adequate LDL-C reduction despite nonstatin therapy
- Virtual visits may be available for patients in rural/remote locations 1
Why Ezetimibe First?
Ezetimibe is prioritized over bempedoic acid in cost-constrained situations because 2:
- Generically available worldwide
- Much cheaper than bempedoic acid
- Easy to access without special storage requirements
- No injection requirements
- Proven cardiovascular outcomes data
- Excellent safety profile comparable to placebo 3
The 2022 BMJ guideline explicitly notes that ezetimibe is "more expensive than statins but much cheaper than PCSK9 inhibitors" and by extension, other newer agents like bempedoic acid 2.
Combination Therapy Approach
If ezetimibe monotherapy provides insufficient LDL-C lowering:
Ezetimibe + BAS combination 1:
- Take ezetimibe either ≥2 hours before or ≥4 hours after BAS to avoid absorption interference
- Can achieve moderate-intensity statin-equivalent LDL-C reduction
- Both agents work through different mechanisms (absorption vs. bile acid binding)
Monitoring and Follow-Up
- Lipid panel: 4-12 weeks after initiating therapy
- Assess tolerability: Particularly GI symptoms if using BAS
- Reassess cardiovascular risk: Determine if LDL-C goals are met
- Document response: Important for potential future prior authorization if bempedoic acid becomes necessary
Common Pitfalls to Avoid
- Don't assume all muscle symptoms are statin-related: Consider other causes (hypothyroidism, vitamin D deficiency, other medications) 4
- Don't overlook lifestyle modifications: Dietary counseling (Mediterranean diet) and exercise remain foundational 1
- Don't forget drug interactions with BAS: Separate administration from other medications by 2-4 hours 1
- Don't dismiss bempedoic acid entirely: If patient qualifies for assistance programs, actual out-of-pocket cost may be substantially lower than $400 1